Pfizer (PFE) Receives “Neutral” Rating from Nord/LB
Other analysts also recently issued reports about the company. Zacks Investment Research upgraded Pfizer from a hold rating to a buy rating and set a $40.00 price target for the company in a report on Tuesday, October 3rd. Vetr downgraded Pfizer from a buy rating to a hold rating and set a $35.71 price target for the company. in a report on Wednesday, September 13th. BMO Capital Markets set a $39.00 price target on Pfizer and gave the stock a buy rating in a report on Tuesday, October 31st. Sanford C. Bernstein set a $39.00 price target on Pfizer and gave the stock a buy rating in a report on Tuesday, September 19th. Finally, Deutsche Bank set a $38.00 price target on Pfizer and gave the stock a buy rating in a report on Wednesday, December 6th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have assigned a buy rating to the company’s stock. Pfizer currently has an average rating of Buy and a consensus target price of $38.77.
Shares of Pfizer (NYSE:PFE) opened at $36.33 on Wednesday. The firm has a market capitalization of $216,550.00, a price-to-earnings ratio of 22.29, a P/E/G ratio of 2.55 and a beta of 1.01. Pfizer has a 1-year low of $30.90 and a 1-year high of $37.35. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56.
Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The business had revenue of $13.17 billion during the quarter, compared to the consensus estimate of $13.17 billion. During the same period in the prior year, the business posted $0.61 earnings per share. Pfizer’s quarterly revenue was up .9% on a year-over-year basis. equities analysts anticipate that Pfizer will post 2.59 EPS for the current fiscal year.
Pfizer declared that its Board of Directors has authorized a stock buyback plan on Monday, December 18th that allows the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization allows the biopharmaceutical company to buy shares of its stock through open market purchases. Shares repurchase plans are often an indication that the company’s board believes its shares are undervalued.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 1st. Investors of record on Friday, February 2nd will be given a $0.34 dividend. This is a boost from Pfizer’s previous quarterly dividend of $0.32. The ex-dividend date is Thursday, February 1st. This represents a $1.36 annualized dividend and a yield of 3.74%. Pfizer’s dividend payout ratio (DPR) is presently 78.53%.
In related news, EVP Alexander R. Mackenzie sold 7,350 shares of the firm’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $35.65, for a total value of $262,027.50. Following the transaction, the executive vice president now owns 117,432 shares of the company’s stock, valued at approximately $4,186,450.80. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Rady A. Johnson sold 8,000 shares of the firm’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $37.07, for a total transaction of $296,560.00. Following the completion of the transaction, the executive vice president now directly owns 46,963 shares in the company, valued at approximately $1,740,918.41. The disclosure for this sale can be found here. In the last ninety days, insiders sold 36,800 shares of company stock worth $1,327,248. 0.06% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in PFE. Janus Henderson Group PLC raised its holdings in shares of Pfizer by 243.5% in the 2nd quarter. Janus Henderson Group PLC now owns 13,175,187 shares of the biopharmaceutical company’s stock worth $442,574,000 after purchasing an additional 9,339,749 shares during the period. Vanguard Group Inc. grew its stake in Pfizer by 2.3% in the 2nd quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock valued at $14,062,088,000 after buying an additional 9,239,499 shares in the last quarter. Renaissance Technologies LLC purchased a new position in Pfizer in the 2nd quarter valued at approximately $268,389,000. Canada Pension Plan Investment Board grew its stake in Pfizer by 249.6% in the 2nd quarter. Canada Pension Plan Investment Board now owns 10,713,626 shares of the biopharmaceutical company’s stock valued at $359,871,000 after buying an additional 7,649,416 shares in the last quarter. Finally, Stifel Financial Corp grew its stake in Pfizer by 5,413.5% in the 3rd quarter. Stifel Financial Corp now owns 7,360,192 shares of the biopharmaceutical company’s stock valued at $262,515,000 after buying an additional 7,226,697 shares in the last quarter. 69.75% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://theolympiareport.com/2017/12/28/pfizer-pfe-receives-neutral-rating-from-nordlb.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with Analyst Ratings Network's FREE daily email newsletter.